Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Prostate Cancer
Interventions
RADIATION

HDR brachytherapy monotherapy

"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."

Trial Locations (1)

J8P 7H2

CSSS de Gatineau, Gatineau

All Listed Sponsors
lead

CSSS de Gatineau

OTHER